Commenting, Mr. Lakshmi N. Mittal, ArcelorMittal Executive Chairman, said:
“2020 was a year of enormous challenge as countries, societies and businesses across the world grappled with the disruption caused by the COVID-19 pandemic. The impact on the steel industry was significant, but I am very proud of the resilience and enterprise shown by our people across the business which enabled ArcelorMittal to deliver a solid operating performance in times of adversity. We have fantastic teams across our operations.
Indeed, 2020 was a milestone year for the Company. Achieving our $7 billion net debt target marked the end of a long-term deleveraging program, and the start of a new phase which will allow the Company to focus on delivering sustainable shareholder returns as we continue to transform for the future. This process will be supported by changes we made to our portfolio, increasing the quality of its earnings potential, and by the investments we are making in high-growth projects
Press Releases
Melbourne, Australia – February 11, 2021
Infosys (NYSE: INFY), a global leader in next-generation digital services and consulting and the Australian Open’s Official Digital Innovation Partner, this year is applying technology to enhance tennis experiences for those onsite and those unable to attend in person. Using digital as an equaliser to bridge the physical gap, Infosys and Tennis Australia are opening up new possibilities by leveraging cloud, AI, 3D virtual experiences and mobility. The innovations are envisioned to alter the sporting normal well beyond the current Grand Slam and represent a shift towards placing digital at the core of the tournament to elevate immersion, passion, brilliance and experience for those on court and across the globe.
(1)
Urovant Sciences (Nasdaq: UROV) announced today that the independent Data and Safety Monitoring Board (DSMB) has recommended the continuation of the phase 2a study of URO-902, a novel gene therapy product, in patients with overactive bladder (OAB) and urge urinary incontinence (UUI).
URO-902 has the potential to be the first gene therapy for patients with OAB. Following the recommendation of the DSMB, Urovant is proceeding with opening cohort 2 of the study with a dose of 48 mg or placebo.
About the Phase 2a Study
This randomized, double blind, placebo-controlled study will evaluate the efficacy, safety, and tolerability of a single administration of URO-902, a novel gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy. URO-902 is administered via direct intradetrusor injections into the bladder wall under local anesthesia in patients who are experiencing OAB symptoms and UUI.